The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Biond; CytomX Therapeutics
Honoraria - Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; cCam Biotherapeutics; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; Novartis; Oncorus; Roche; Sellas Life Sciences; Takeda; WindMIL
Consulting or Advisory Role - Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Jounce Therapeutics; Kirin Pharmaceuticals; Lion Biotechnologies; Merck; Moderna Therapeutics; Nektar; Novartis; Oncorus; Roche; Sellas Life Sciences; Takeda Science Foundation; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Merck; Novartis; Roche; Takeda
 
Hao Tang
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb (I)
Travel, Accommodations, Expenses - Bristol-Myers Squibb (I)
 
Lauren Hippeli
Employment - Brystol-Myers-Squibb
Stock and Other Ownership Interests - Brystol-Myers-Squibb
Travel, Accommodations, Expenses - Brystol-Myers-Squibb
 
Max Qian
Employment - Brystol-Myers-Squibb
Stock and Other Ownership Interests - Brystol-Myers-Squibb
Travel, Accommodations, Expenses - Brystol-Myers-Squibb
 
Megan Wind-Rotolo
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Other Relationship - Huntsworth Health (I)
 
James M.G. Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOnctura; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOnctura; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech
 
Jedd D. Wolchok
Stock and Other Ownership Interests - Adaptive Biotechnologies; Ascentage Pharma; Beigene; Elucida Oncology; ImVaq; Kleo Pharmaceuticals; Linneaus; Potenza Therapeutics; Serametrix; Tizona Therapeutics, Inc.; Trieza Therapeutics
Honoraria - Amercian Association for Cancer Research; Esanex; Institut Jules Bordet Instituut
Consulting or Advisory Role - Adaptive Biotechnologies; Advaxis; Amgen; Apricity Therapeutics; Array BioPharma; Ascentage Pharma; Astellas Pharma; Bayer; Beigene; Bristol-Myers Squibb; Celgene; Chugai Pharma; F-Star Biotechnology; Genentech; Kleo Pharmaceuticals; Lilly; MedImmune; Merck; Neon Therapeutics; Ono Pharmaceutical; Polaris; Polynoma; Potenza Therapeutics; PsiOxus Therapeutics; PsiOxus Therapeutics; PureTech; Sellas Life Sciences; Serametrix; Surface Oncology; Syndax; Tizona Therapeutics, Inc.; Trieza Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); F-Star Therapeutics; Genentech/Roche (Inst); Incyte (Inst); Leap Therapeutics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2; Engineered Vaccinia Viruses for Cancer Immunotherapy; I am a co-inventor and receive royalties for a blood test for monitoring myeloid derived suppressor cells.; I am a co-inventor on a patent for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy; I am a co-inventor on a patent for CAR+ T cells targeting differentiation antigens as means to treat cancer; I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus.; I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals.; I am co-inventor and receive royalties for a patent for immune modulating antibodies.
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bristol-Myers Squibb; Celegene Therapeutics; Chugai Pharma; Janssen; MedImmune; Novartis; Ono Pharmaceutical; Potenza Pharmaceuticals; Roche; Tizona Therapeutics, Inc.
 
Mario Sznol
Stock and Other Ownership Interests - Actym Therapeutics; Adaptive Biotechnologies; Amphivena; Intensity Therapeutics; Torque
Consulting or Advisory Role - Abbvie; Adaptimmune; Allakos; Almac Diagnostics; Array BioPharma; AstraZeneca/MedImmune; Biodesix; Bristol-Myers Squibb; Celldex; Genentech/Roche; Genmab; Gritstone Oncology; Hinge; immunocore; Incyte; Innate Pharma; Inovio Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck Sharp & Dohme; Modulate; Molecular Partners; Nektar; Newlink Genetics; Novartis; Omniox; Pieris Pharmaceuticals; Pierre Fabre; Seattle Genetics; Symphogen; Theravance; Torque
Other Relationship - AcademicCME; Clinical Care Options; DAVAOncology; Haymarket Media; Imedex; Physician Education Resource; Prime Oncology; Research to Practice; TRM Oncology; Vindico
 
Caroline Robert
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Pierre Fabre; Roche
 
David Michael Woods
Stock and Other Ownership Interests - Bristol-Myers Squibb; Lion Biotechnologies
Research Funding - Acetylon Pharmaceuticals (Inst); Mirati Therapeutics
Patents, Royalties, Other Intellectual Property - Patent for the targeting HDAC11
 
Andressa Sodre Laino
Research Funding - Mirati Therapeutics (Inst); NextCure (Inst)
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity
Consulting or Advisory Role - Aduro Biotech; Amgen; Bayer; Bristol-Myers Squibb; Celldex; EMD Serono; Genentech/Roche; Incyte; Incyte; Incyte; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche